BridgeBio Pharma, Inc.
BBIO
$66.54
$2.013.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 126.26% | 62.46% | 7.62% | -41.71% | 2,285.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 126.26% | 62.46% | 7.62% | -41.71% | 2,285.27% |
| Cost of Revenue | 440.54% | 524.54% | 275.17% | 147.35% | 58.54% |
| Gross Profit | 120.67% | 57.33% | 4.66% | -43.80% | 3,079.58% |
| SG&A Expenses | 83.86% | 93.57% | 91.25% | 77.82% | 91.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.63% | 26.42% | 22.08% | 17.47% | 31.30% |
| Operating Income | 13.04% | -11.69% | -28.38% | -44.83% | 3.68% |
| Income Before Tax | -35.10% | -80.15% | -69.39% | -23.59% | 17.00% |
| Income Tax Expenses | -62.27% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.89% | -80.53% | -70.09% | -23.80% | 16.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.56% | 15.46% | 11.60% | 4.87% | -24.52% |
| Net Income | -35.31% | -81.63% | -71.08% | -24.10% | 16.70% |
| EBIT | 13.04% | -11.69% | -28.38% | -44.83% | 3.68% |
| EBITDA | 13.07% | -12.01% | -28.92% | -45.60% | 3.65% |
| EPS Basic | -32.90% | -73.58% | -55.29% | -9.37% | 27.90% |
| Normalized Basic EPS | 1.24% | -20.33% | -28.78% | -35.63% | 9.58% |
| EPS Diluted | -32.90% | -73.58% | -55.29% | -9.37% | 27.90% |
| Normalized Diluted EPS | 1.24% | -20.33% | -28.78% | -35.63% | 9.58% |
| Average Basic Shares Outstanding | 2.93% | 4.48% | 7.75% | 11.62% | 14.33% |
| Average Diluted Shares Outstanding | 2.93% | 4.48% | 7.75% | 11.62% | 14.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |